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VEGF maintains renal structure 
and function under normotensive 
and hypertensive conditions
Vascular endothelial growth factor (VEGF) is essential for 
embryonic vascular development and angiogenesis in many 
medical conditions. However, recent studies have described 
an important role of VEGF in endothelial-cell homeostasis. 
In the kidney, gene deletion and antibody-based studies have 
demonstrated a pivotal role for VEGF in the developmental 
regulation of the glomerular capillary network, but its actions 
in the normal adult kidney and its role in renal disease are 
poorly understood. In a recent publication, Advani et al. 
examined the eﬀect of VEGF inhibition on renal structure 
and function under physiological conditions and during 
activation of the renin–angiotensin system as well as systemic 
hypertension. They found that, compared with normotensive 
rats, glomerular VEGF mRNA was increased in the 
kidneys of spontaneously hypertensive rats and was more 
increased in the glomeruli of transgenic (mRen-2)27 rats 
with hypertension due to overexpression of renin (Figure). 
Interestingly, administration of either an orally active 
inhibitor of the type 2 VEGF receptor (VEGFR-2) tyrosine 
kinase or a VEGF neutralizing antibody to TGR(mRen-2)27  
rats resulted in loss of glomerular endothelial cells and 
transformation to a malignant hypertensive phenotype with 
severe glomerulosclerosis. In contrast, normotensive and 
spontaneously hypertensive rats better tolerated VEGFR-2 
kinase inhibition but showed a detectable endothelial-cell 
loss in glomeruli and albuminuria. These studies demonstrate 
that, as shown in other endothelia, VEGF has a role in the 
maintenance of glomerular endothelial integrity under 
normal homeostatic conditions. In addition, glomerular 
VEGF expression is increased in response to hypertension, 
particularly when the hypertension is due to activation of the 
renin–angiotensin system. VEGF has a protective role for 
glomerular endothelium under these conditions. (Proc Natl 
Acad Sci USA 2007; 104: 14448–14453)
Juan Oliver
Angiotensin II regulates trafficking 
in and out of plasma membrane of 
the Na+-Cl– cotransporter
The Na+-Cl– cotransporter (NCC), expressed in the apical 
membrane of the distal convoluted tubule (DCT), is the target of 
the thiazide diuretics. The importance of NCC in the regulation 
of salt balance and thus blood pressure is demonstrated in the 
genetic disorder Gitelman’s syndrome, in which loss-of-function 
mutations in NCC result in salt wasting, hypokalemia, and 
hypotension. Studies in mice with NCC knocked out show that, 
on low-sodium diets, blood pressure is signiﬁcantly reduced 
when compared with that of control mice. The abundance of 
NCC in the DCT is regulated by dietary salt and aldosterone. In 
addition, the ratio of NCC present at the apical membrane versus 
intracellular pools changes during chronic changes in dietary 
salt, with less NCC present in the apical membrane during high-
salt intake than during low-salt intake conditions. This suggests 
that traﬃcking of the NCC to and from the plasma membrane 
may be a mechanism to acutely regulate the transporter.
Angiotensin II, a potent vasoconstrictor and sodium-retaining 
hormone, has been shown to be involved in regulating the 
abundance of major renal sodium transporters such as ENaC, 
NKCC2, and others. In addition, angiotensin regulates traﬃcking 
of the proximal tubule sodium transporter NHE3. The DCT con-
tains angiotensin II type 1 receptors in its luminal and basolateral 
membranes; activation by the hormone stimulates transport of 
bicarbonate, ﬂuid, and sodium in this part of the nephron. In a 
recent study, Sandberg et al. used immunoelectron microscopy 
to ﬁnd that acute infusion of the angiotensin-converting enzyme 
inhibitor captopril provoked traﬃcking of NCC from apical 
plasma membranes to subapical cytoplasmic vesicles, which was 
reversed by acute angiotensin II infusion (Figure). In addition, 
on density gradients of renal cortex, captopril provoked redis-
tribution of 27.3% of total NCC from low-density apical plasma 
membrane-enriched membranes to higher-density membranes, 
In situ hybridization autoradiographs of kidney sections probed for  
VEGF-A. (a) Normotensive rat. (b) Spontaneously hypertensive rat (SHR). 
(c) TGR(mRen-2)27 rat.
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Immunoelectron microscope localization of NCC in DCT cells of control 
rats (a) and rats infused with captopril (b and d) or captopril plus 
angiotensin II (c). Scale bars, 1 µm.
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and angiotensin II plus captopril restored the NCC to apical 
plasma membrane-enriched fractions. Redistribution occurred 
independent of a change in NCC total abundance. Thus, the 
study demonstrates that angiotensin II acutely regulates traf-
ﬁcking of NCC in and out of the DCT plasma membrane. This 
action is very likely to be important in regulating DCT Na+ 
reabsorption and provides another mechanism whereby the 
renin–angiotensin system contributes to sodium balance. (Am J 
Physiol Renal Physiol 2007; 293: F662–F669)
Juan Oliver
Cysteine redox sensor in PKGIα 
explains hydrogen peroxide 
vasodilation
Oxidant molecules can cause cellular damage and disease, 
but they also play crucial roles in homeostatic functions of 
healthy cells and tissues. Modiﬁcation of proteins by oxidant 
species with a secondary change in function allows cells to 
sense oxidants and, therefore, inﬂuence biological responses. 
The covalent attachment of nitrogen monoxide to the thiol 
side chain of cysteine (S-nitrosylation) has emerged as an 
important mechanism for post-translational regulation of 
many proteins and is a classical mechanism for redox-based 
physiological regulation. While S-nitrosylation is a critical 
mechanism mediating nitric oxide’s regulation of cellular 
signaling, regulation of protein function by reversible cysteine-
targeted oxidation can be achieved by other mechanisms, such 
as S-glutathiolation and sulfenyl/amide formation, as well as 
intramolecular disulﬁde bonding of vicinal thiols. Burgoyne et 
al. now report that guanosine 3′,5′-monophosphate (cGMP)-
dependent protein kinase (PKG), a critical enzyme regulating 
vascular smooth muscle tone, functions directly as a redox 
sensor. In cells exposed to exogenous hydrogen peroxide 
(H2O2), the Iα isoform of the enzyme, PKGIα, formed an 
interprotein disulﬁde linking its two subunits, and this oxidation 
directly activated the kinase. The authors showed that the aﬃnity 
of the kinase for substrates it phosphorylates was enhanced 
by disulﬁde formation. Interestingly, disulﬁde formation of 
PKGIα was also induced by insulin, a hormone that is known to 
increase H2O2 concentration through stimulation of superoxide-
generating oxidases. Thus, oxidation-induced activation of PKG 
represents an alternate mechanism for regulation along with 
the classical activation involving nitric oxide and cGMP. This 
mechanism demonstrates a cGMP-independent vasorelaxation 
in response to oxidants in the cardiovascular system. Shear stress 
causes vasodilation and induces endothelial release of H2O2. 
The current results provide a molecular explanation for how 
H2O2 can operate as an endothelium-derived hyperpolarizing 
factor and appear to provide a mechanism for ﬂow-induced 
vasodilation. (Science 2007; 317: 1393–1397)
Juan Oliver
Effects of perindopril and 
indapamide on hypertension in 
patients with type 2 diabetes
Blood pressure is an important determinant of the risks of 
macrovascular and microvascular complications of type 2 
diabetes. Guidelines recommend that patients with diabetes 
and hypertension intensively lower their blood pressure. 
The ADVANCE Collaborative Group assessed the eﬀects 
of the routine administration of an angiotensin-converting 
enzyme inhibitor–diuretic combination on serious vascular 
events in patients with diabetes, irrespective of initial blood 
pressure levels or the use of other blood pressure-lowering 
drugs. The trial was conducted in 215 collaborating centers 
in 20 countries. After a 6-week active run-in period, 
11,140 patients with type 2 diabetes were randomized to 
treatment with a ﬁxed combination of perindopril and 
indapamide or matching placebo, in addition to current 
therapy. The primary end points were composites of major 
macrovascular and microvascular events, deﬁned as death 
from cardiovascular disease, non-fatal stroke or non-fatal 
myocardial infarction, and new or worsening renal or 
diabetic eye disease, and analysis was by intention to treat. 
The macrovascular and microvascular composites were 
analyzed jointly and separately. After a mean of 4.3 years of 
follow-up, 73% of those assigned active treatment and 74% of 
those assigned control remained on randomized treatment. 
Compared with patients assigned to placebo, those on active 
therapy had a mean reduction of 5.6 mm Hg in systolic blood 
pressure and of 2.2 mm Hg in diastolic blood pressure. The 
relative risk of a major macrovascular or microvascular 
event was reduced by 9% (861 (15.5%) in those on active 
therapy versus 938 (16.8%) placebo; hazard ratio 0.91, 
95% conﬁdence interval 0.83–1.00, P = 0.04). The separate 
reductions in macrovascular and microvascular events were 
similar in both groups but not independently signiﬁcant 
(macrovascular, 0.92; 0.81–1.04, P = 0.16; microvascular, 
0.91; 0.80–1.04, P = 0.16). The relative risk of death from 
cardiovascular disease was reduced by 18% (211 (3.8%) in 
the active group versus 257 (4.6%) placebo; 0.82, 0.68–0.98, P 
= 0.03), and death from any cause was reduced by 14% (408 
(7.3%) versus 471 (8.5%) placebo; 0.86, 0.75–0.98, P = 0.03). 
There was no evidence that the eﬀects of the study treatment 
diﬀered by initial blood pressure level or concomitant use 
of other treatments at baseline. Routine administration of a 
ﬁxed combination of perindopril and indapamide to patients 
with type 2 diabetes was well tolerated and reduced the 
risks of major vascular events, including death. Despite the 
wide conﬁdence limits, the results suggest that patients with 
diabetes and hypertension would beneﬁt from treatment with 
perindopril and indapamide. (Lancet 2007; 370: 829–840)
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